Warnex expands reach in European market
"While still in the early stages of the commercial rollout of our Rapid Pathogen Detection System, we expect the addition of AES to our European distribution network to significantly expand our presence in key countries in the EU market, supplementing our existing relationships for Italy and the U.K.," said Mark Busgang, President & CEO of Warnex. "Building on our recent regulatory validations and success with early adopters, we are working hard to push our international commercialization strategy forward and building our sales force in North America."
AES Laboratoire is one of the leading French manufacturers and suppliers of laboratory equipment, diagnostic tests and consumables for microbiological analysis in the food, pharmaceutical and veterinary industries. The Company had revenue of (euro) 69 million last year and has 270 employees.
"AES has a reputation for providing high quality pathogen detection solutions and has enjoyed significant success in the commercialization of innovative new technologies by leveraging our extensive sales network, which extends across the EU," said Alain Le Roch, President of AES Laboratoire. "We look forward to marketing Warnex's Rapid Pathogen Detection System to our customers who place a premium on product safety and understand the value of a reliable, high speed testing platform."
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.